Combined chemotherapy of irinotecan/platinum in extensive disease SCLC / 实用肿瘤学杂志

Small cell lung cancer(SCLC),characterized with rapid growth and early metastasis ,accounts for about 15~20 percent of all kinds of lung cancer .Patients with extensive disease of SCLC should be treated with combined chemotherapy .The standard treatment for extensive SCLC is etoposide combined with platinum , shortly for EP,with no breakthrough progress in the last decades .This paper briefly reviews the combination of iri-notecan/platinum that showed effectiveness and safety in the treatment of extensive SCLC .